Ferric derisomaltose for treating iron deficiency anemia

Published on 02 Jan 2024
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended ferric derisomaltose for inclusion on the MOH List of Subsidised Drugs for treating iron deficiency anaemia due to unfavourable cost-effectiveness compared with ferric carboxymaltose at the price proposed by the manufacturer.

Ferric derisomaltose for treating iron deficiency anemia (Published 2 Jan 2024) [PDF, 89 KB]